Isabel Kalofonos

Insider Reports History

Location
San Diego, CA
Signature
/s/ Tobin Schilke, as attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Isabel Kalofonos:

Company Role Class Num Shares Value Price $ Report Date Ownership
Crinetics Pharmaceuticals, Inc. Chief Commercial Officer Common Stock 834 $45,870 $55.00 05 Jan 2026 Direct
ImmunoGen, Inc. SVP & CHIEF COMMERCIAL OFFICER Restricted Stock Unit 0 $0 $29.30 12 Feb 2024 Direct
ImmunoGen, Inc. SVP & CHIEF COMMERCIAL OFFICER Stock Option (Right to Buy) 0 $0 $5.19 12 Feb 2024 Direct
Crinetics Pharmaceuticals, Inc. Chief Commercial Officer Stock Option (Right to Buy) 97,500 05 Jan 2026 Direct

Insider Reports Filed by Isabel Kalofonos

Symbol Company Period Transactions Value $ Form Type Role Filing Time
CRNX Crinetics Pharmaceuticals, Inc. 05 Jan 2026 3 -$36,025 4 Chief Commercial Officer 07 Jan 2026, 17:11
CRNX Crinetics Pharmaceuticals, Inc. 10 Jan 2025 1 $0 4 Chief Commercial Officer 13 Jan 2025, 16:30
CRNX Crinetics Pharmaceuticals, Inc. 16 Dec 2024 0 $0 3 Chief Commercial Officer 30 Dec 2024, 16:30
/report/000110465924014700-kalofonos-isabel-2024-02-12 ImmunoGen, Inc. 12 Feb 2024 3 $0 4 SVP & CHIEF COMMERCIAL OFFICER 12 Feb 2024, 16:38
/report/000141588924002765-kalofonos-isabel-2024-02-01 ImmunoGen, Inc. 01 Feb 2024 1 $0 4 SVP & CHIEF COMMERCIAL OFFICER 05 Feb 2024, 21:30
/report/000141588923007094-kalofonos-isabel-2023-04-28 ImmunoGen, Inc. 28 Apr 2023 2 $0 4 SVP & CHIEF COMMERCIAL OFFICER 02 May 2023, 16:32
/report/000141588923007093-kalofonos-isabel-2023-04-24 ImmunoGen, Inc. 24 Apr 2023 0 $0 3 SVP & CHIEF COMMERCIAL OFFICER 02 May 2023, 16:30